金吾财讯 | 中信里昂发研指，康方生物(09926)较早前刊发公告指，旗下治疗肺癌药物三期临床试验取得显着阳性结果，为双特异性抗体新药依达方，联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的III期头对头临床试验，经独立数据监察委员会评估，期中分析显示强阳性结果，达到无进展生存期的主要研究终点。研究详细数据将在今年相关国际术会议上公布。该行认为公司治疗肺癌药物临床试验时间表稍早于该行预期，应对公司销售增长有正面作用。该行维持“优于大市”评级，并上目标价18%，由95.3港元调整至112.6港元，
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.